FDA Orange Book · active-ingredient family
Estrogens, esterified
Estrogens, esterified is approved in 18 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
0
Brand (NDA)
18
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Generic (ANDA) products (18)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| AMNESTROGEN×4 | BRISTOL MYERS SQUIBB | ANDA 083266 | — | Approved Prior to Jan 1, 1982 | |
| ESTERIFIED ESTROGENS | PVT FORM | ANDA 083414 | — | Approved Prior to Jan 1, 1982 | |
| ESTERIFIED ESTROGENS | PVT FORM | ANDA 083765 | — | Approved Prior to Jan 1, 1982 | |
| ESTERIFIED ESTROGENS | PVT FORM | ANDA 085907 | — | Approved Prior to Jan 1, 1982 | |
| ESTERIFIED ESTROGENS | SANDOZ | ANDA 085302 | — | Approved Prior to Jan 1, 1982 | |
| ESTRATAB | SOLVAY | ANDA 086715 | — | Approved Prior to Jan 1, 1982 | |
| ESTRATAB | SOLVAY | ANDA 083209 | — | Approved Prior to Jan 1, 1982 | |
| ESTRATAB | SOLVAY | ANDA 083856 | — | Approved Prior to Jan 1, 1982 | |
| ESTRATAB | SOLVAY | ANDA 083857 | — | Approved Prior to Jan 1, 1982 | |
| EVEX | ROCHE PALO | ANDA 084215 | — | Approved Prior to Jan 1, 1982 | |
| EVEX | ROCHE PALO | ANDA 083376 | — | Approved Prior to Jan 1, 1982 | |
| FEMOGEN | PVT FORM | ANDA 085076 | — | Approved Prior to Jan 1, 1982 | |
| FEMOGEN | PVT FORM | ANDA 085008 | — | Approved Prior to Jan 1, 1982 | |
| FEMOGEN | PVT FORM | ANDA 085007 | — | Approved Prior to Jan 1, 1982 | |
| MENEST | MONARCH PHARMS | ANDA 084951 | — | Approved Prior to Jan 1, 1982 | |
| MENEST | MONARCH PHARMS | ANDA 084948 | — | Approved Prior to Jan 1, 1982 | |
| MENEST | MONARCH PHARMS | ANDA 084950 | — | Approved Prior to Jan 1, 1982 | |
| MENEST | MONARCH PHARMS | ANDA 084949 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Estrogens, esterified — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

